Besides, the correlation and possible combination with other validated biomarkers, such as TILs, PD-L1 expression on tumor-infiltrating immune cells and TMB, should also be analyzed to provide a better prognostic signature of immunotherapy in lung cancer. This evidence concerns the gene CD274 and lung carcinoma.